Actualités Theratechnologies Inc - TH | Actions Toronto Stock Exchange

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and...

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all...

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE...

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding...

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

MONTREAL, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Resumes Distribution of EGRIFTA SV®

MONTREAL, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Provides Update on EGRIFTA SV® Supply

MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

MONTREAL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

MONTREAL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary...

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Addition of investigational RNA-targeted medicines build upon Theratechnologies’ foundational HIV portfolio...

Theratechnologies Announces Resumed Production of EGRIFTA SV®

MONTREAL, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH)

Outils de qualité professionnelle, pour des investisseurs individuels.

TH Actualités

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Theratechnologies Resumes Distribution of EGRIFTA SV®

Theratechnologies Provides Update on EGRIFTA SV® Supply

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Theratechnologies Announces Resumed Production of EGRIFTA SV®

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH) Actualités

Theratechnologies Inc (TH)

Outils de qualité professionnelle, pour des investisseurs individuels.

TH Actualités

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Theratechnologies Resumes Distribution of EGRIFTA SV®

Theratechnologies Provides Update on EGRIFTA SV® Supply

Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

Theratechnologies Announces Resumed Production of EGRIFTA SV®

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités